{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:20:03Z","timestamp":1773332403980,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jim.2019.112675","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T11:18:26Z","timestamp":1571311106000},"page":"112675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies"],"prefix":"10.1016","volume":"476","author":[{"given":"Grzegorz","family":"Stasi\u0142oj\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Felberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Okr\u00f3j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2019.112675_bb0005","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.4049\/jimmunol.1103693","article-title":"Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients","volume":"188","author":"Beurskens","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2019.112675_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jim.2019.112675_bb0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-019-02304-0","article-title":"Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics","volume":"68","author":"Felberg","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2019.112675_bb0020","first-page":"1476","article-title":"Effect of alemtuzumab on neoplastic B cells","volume":"89","author":"Golay","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jim.2019.112675_bb0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","article-title":"Complement resistance of tumor cells: basal and induced mechanisms","volume":"36","author":"Jurianz","year":"1999","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jim.2019.112675_bb0030","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1749-6632.2009.04803.x","article-title":"Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement\/rituximab interactions & clinical results in refractory CLL","volume":"1173","author":"Klepfish","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jim.2019.112675_bb0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12032-013-0759-5","article-title":"Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement","volume":"30","author":"Okroj","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jim.2019.112675_bb0040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ctrv.2012.10.008","article-title":"Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies","volume":"39","author":"Okroj","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jim.2019.112675_bb0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/mol.114.092684","article-title":"Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies","volume":"86","author":"Taylor","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jim.2019.112675_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2741\/3688","article-title":"Molecular mechanisms of the antitumor effects of anti-CD20 antibodies","volume":"16","author":"Winiarska","year":"2010","journal-title":"Front. Biosci."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175919302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175919302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:35:38Z","timestamp":1758299738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175919302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"alternative-id":["S0022175919302832"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2019.112675","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2019.112675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112675"}}